Old Drugs, New Indications (Review)

Introduction. The drug can be used in the treatment of one disease and for the prevention and treatment of another pathological process. This is possible due to the repurposing of medicines. Creating drugs from scratch takes a long time to develop and implement, which leads to large financial costs, and also has a high dropout rate of candidate substances and requires significant financial costs. The main advantage of repurposing instead of creating new drug is relatively low financial costs and a significant reduction in the first two phases of clinical trials.Text. Drug repurposing is based on pharmacology, pharmacokinetics, pharmacodynamics, pharmaceuticals and clinical trials, where the first two phases are significantly reduced compared to the creation of a completely new. There are examples of successful repurposing and negative side effects with off-label drug use, which is unsafe but the best solution for orphan diseases. A targeted search for the possibility of repurposing drugs using an automatic procedure is being carried out, where a large number of chemical compounds are tested for activity or affinity for receptors and enzymes – high-throughput screening. Computer design has become widespread, which or repurposing "in silico", where information about the drug is used: targets, chemical structures, metabolic pathways, side effects, followed by the construction of appropriate models. Machine learning (ML) algorithms: Bayes classifier, logistic regression, support vector machine, decision tree, random forest and others are successfully used in biochemical pharmaceutical, toxicological research. But the most promising development of reprofiling is associated with the use of deep neural networks (DNN). Using deep learning, DNN were found to outperform other algorithms for drug development and toxicity prediction.Conclusion. Currently, interest in drug repurposing has grown markedly. A search for the keywords «drug repurposing» showed 2,422 articles on the problem of new uses for drugs that already exist in medicine.

[1]  P. Cyr,et al.  Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. , 2022, Journal of managed care & specialty pharmacy.

[2]  S. Suslina,et al.  Development of Celecoxib Granules for Manufacturing of Prolonged Release Celecoxib Capsules and Tablets , 2022, Drug development & registration.

[3]  P. Cowen,et al.  The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study , 2021, Journal of psychopharmacology.

[4]  Vagan Y. Terziyan,et al.  Neural Networks With Disabilities: An Introduction to Complementary Artificial Intelligence , 2021, Neural Computation.

[5]  H. Hermjakob,et al.  Path4Drug: Data Science Workflow for Identification of Tissue-Specific Biological Pathways Modulated by Toxic Drugs , 2021, Frontiers in Pharmacology.

[6]  R. Mittal,et al.  Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. , 2021, European journal of pharmacology.

[7]  N. Vargesson,et al.  Thalidomide: history, withdrawal, renaissance, and safety concerns , 2021, Expert opinion on drug safety.

[8]  R. Goldman,et al.  Bupropion for smoking cessation in adolescents , 2021, Canadian Family Physician Médecin de famille canadien.

[9]  H. Pérez‐Sánchez,et al.  Ligand-based virtual screening, molecular docking, and molecular dynamics of eugenol analogs as potential acetylcholinesterase inhibitors with biological activity against Spodoptera frugiperda , 2021, Molecular Diversity.

[10]  Vivek P. Chavda,et al.  Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds , 2021, Frontiers in Pharmacology.

[11]  H. Sonaye,et al.  Drug repurposing: Iron in the fire for older drugs. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  C. Arce,et al.  The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer , 2021, Frontiers in Oncology.

[13]  E. Jimenez‐Solem,et al.  Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study , 2021, Drugs - Real World Outcomes.

[14]  E. Carboni,et al.  Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? , 2021, Frontiers in Neuroscience.

[15]  Pravir Kumar,et al.  Artificial intelligence to deep learning: machine intelligence approach for drug discovery , 2021, Molecular Diversity.

[16]  N. Knoers,et al.  Drug Repurposing for Rare Diseases. , 2021, Trends in pharmacological sciences.

[17]  Fang-Xiang Wu,et al.  Drug-drug similarity measure and its applications. , 2020, Briefings in bioinformatics.

[18]  M. Ayoub,et al.  Sildenafil in combination therapy against cancer: A literature review. , 2020, Current medicinal chemistry.

[19]  N. Kalin,et al.  Hormonal Treatments for Major Depressive Disorder: State of the Art. , 2020, The American journal of psychiatry.

[20]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[21]  V V Poroikov,et al.  Computer-Aided Drug Design: from Discovery of Novel Pharmaceutical Agents to Systems Pharmacology , 2020, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.

[22]  C. Bailly Irinotecan: 25 years of cancer treatment. , 2019, Pharmacological research.

[23]  Sean Ekins,et al.  Exploiting machine learning for end-to-end drug discovery and development , 2019, Nature Materials.

[24]  J. Posner The Role of Precision Medicine in Child Psychiatry: What Can We Expect and When? , 2018, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  S. Karahuseyinoglu,et al.  C-Abl is not actıvated in DNA damage-induced and Tap63-mediated oocyte apoptosıs in human ovary , 2018, Cell Death & Disease.

[26]  Савинкова Алена Валерьевна,et al.  ВАРИАНТЫ И ПЕРСПЕКТИВЫ ПЕРЕПРОФИЛИРОВАНИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ДЛЯ ИСПОЛЬЗОВАНИЯ В ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ , 2018 .

[27]  D. Herndon,et al.  Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns? , 2017, Journal of child and adolescent psychopharmacology.

[28]  Jacob K. Asiedu,et al.  The Drug Repurposing Hub: a next-generation drug library and information resource , 2017, Nature Medicine.

[29]  M. Toumi,et al.  Filling the gap in CNS drug development: evaluation of the role of drug repurposing , 2017, Journal of market access & health policy.

[30]  Nicola Nosengo Can you teach old drugs new tricks? , 2016, Nature.

[31]  Sergey Plis,et al.  Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. , 2016, Molecular pharmaceutics.

[32]  Günter Klambauer,et al.  DeepTox: Toxicity Prediction using Deep Learning , 2016, Front. Environ. Sci..

[33]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[34]  Geoffrey E. Hinton,et al.  Deep Learning , 2015, Nature.

[35]  F. Leweke,et al.  Drug repurposing and emerging adjunctive treatments for schizophrenia , 2015, Expert opinion on pharmacotherapy.

[36]  Yan Zhao,et al.  Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.

[37]  Francisco Azuaje,et al.  Drug interaction networks: an introduction to translational and clinical applications. , 2013, Cardiovascular research.

[38]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[39]  Julio Saez-Rodriguez,et al.  Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.

[40]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.